ReviewInternational journal of surgery (London, England)2025
Diagnostic and predictive biomarkers of acute rejection after liver transplantation.
Review in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- iTRAQ- and MRM-Based Proteomics Identify Early Injury Biomarkers for Primary Dysfunction After Liver Transplantation.Annals of transplantation · 2026Article
- LDLRJournal of clinical and translational hepatology · 2026Article
- Coordinated Hippo, IFN and NF-κB pathway activation in kidney rejection.Open medicine (Warsaw, Poland) · 2026Article
- Donor-derived cell-free DNA as a noninvasive biomarker for diagnosis and monitoring of acute rejection after liver transplantation.Frontiers in immunology · 2026Article
- Identification and validation of bile exosomal microRNA signatures for diagnosing acute rejection in liver transplant recipients.Frontiers in genetics · 2026Article
- Downregulated PLAU alleviates acute rejection after liver transplantation by targeting Ptgs2 in macrophages.Frontiers in immunology · 2026Article
- Review
- Review Article: Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.Alimentary pharmacology & therapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation serves as a vital therapeutic intervention for individuals suffering from end-stage liver disease globally. A significant complication encountered by liver transplant recipients during the postoperative period is acute rejection, which has traditionally been identified through invasive graft biopsy procedures. Furthermore, assessing the immune status of liver transplant patients is essential for effective posttransplant management and represents a significant advancement toward the personalization of immunosuppressive therapy. Nevertheless, current immunological monitoring after the transplantation predominantly depends on clinical judgment and the measurement of immunosuppressive drug levels, lacking a comprehensive evaluation of actual immune system suppression. In contrast, biomarkers offer a comparatively novel and safer approach for the detection and prediction of transplant rejection, though their clinical application remains constrained due to the absence of prospective validation studies. This review examines the existing literature on potential biomarkers for acute rejection following liver transplantation, and their implications for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.